{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:59:27Z","timestamp":1768319967447,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ajg.2022.10.001","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T13:10:47Z","timestamp":1676898647000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir-based therapy in HCV patients with chronic kidney disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Mohammad","family":"El-Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Elserafy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maissa","family":"El Raziky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa","family":"Elakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Korany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Mehrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabab","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maged","family":"Mahrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadry","family":"Elsaeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehia","family":"Elshazly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahid","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2022.10.001_b0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3350\/cmh.2020.0312","article-title":"Outcomes of hepatitis C virus treatment with ledipasvir\/sofosbuvir in Mongolian population: successes and challenges facing scale-up of care","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.ajg.2022.10.001_b0010","doi-asserted-by":"crossref","first-page":"101596","DOI":"10.1016\/j.clinre.2020.101596","article-title":"Epidemiology of hepatitis C virus infection","volume":"45","author":"Roudot-Thoraval","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ajg.2022.10.001_b0015","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jgh.12313","article-title":"Chronic hepatitis C infection is associated with insulin resistance and lipid profiles","volume":"30","author":"Dai","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ajg.2022.10.001_b0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","article-title":"Hepatitis C and renal disease: An update","volume":"42","author":"Meyers","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.ajg.2022.10.001_b0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis ofobservational studies: Hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ajg.2022.10.001_b0030","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/14656566.2021.1921737","article-title":"An update on direct antiviral agents for the treatment of hepatitis C","volume":"22","author":"Stanciu","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajg.2022.10.001_b0035","unstructured":"Ministry of Health, Egypt, El-Zanaty and associates. Egypt: ICF International. Egypt Health Issues Survey. Cairo, Egypt and Rockville, MD, USA: Ministry of Health and ICF International; 2015."},{"key":"10.1016\/j.ajg.2022.10.001_b0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2022.10.001_b0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J Transl Int Med"},{"issue":"1","key":"10.1016\/j.ajg.2022.10.001_b0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"European Association for the Study of the liver electronic address eee, European Association for the Study of the L: EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2022.10.001_b0055","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct acting antiviral combination for patients with HCV genotype 1 infection and severe renal impairment or end stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajg.2022.10.001_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2016.04.003","article-title":"Finally, safe and effective treatment options for hepatitis C in hemodialysis patients","volume":"65","author":"Bhamidimarri","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2022.10.001_b0065","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2022.10.001_b0070","first-page":"1191","article-title":"The 1975 Declaration of Helsinki and consent","volume":"115","author":"Shephard","year":"1976","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ajg.2022.10.001_b0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2010.09.023","article-title":"Wang X and Fried LF.HCV infection and the incidence of CKD","volume":"57","author":"Butt","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ajg.2022.10.001_b0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/ HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2022.10.001_b0085","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease; pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajg.2022.10.001_b0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clinre.2018.08.003","article-title":"Efficacy of ombitasvir\/paritaprevir\/ritonavir\/ribavirin in management of HCV genotype 4 and end-stage kidney disease","volume":"43","author":"Mekky","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ajg.2022.10.001_b0095","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"Podsadecki T and Bernstein B.ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.N","volume":"370","author":"Poordad","year":"2014","journal-title":"Engl J Med"},{"key":"10.1016\/j.ajg.2022.10.001_b0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2015.10.005","article-title":"Sustained virological response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevier\/r and dasabuvir for 12 weeks","volume":"64","author":"Feld","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2022.10.001_b0105","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1159\/000488965","article-title":"Paritaprevir\/ritonavir\/ombitasvirplusdasabuvir regimen in the treatment of genotype 1 chronic hepatitis C infection in patients with severe renal impairment and end-stage renal disease: a real-life cohort","volume":"43","author":"Sperl","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ajg.2022.10.001_b0110","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/liv.13674","article-title":"High efficacy of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1\u2013infected patients with severe chronic kidney disease","volume":"38","author":"Sanai","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.ajg.2022.10.001_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm7100314","article-title":"Association of renal function and direct-acting antiviral agents for HCV: a network meta-analysis","volume":"7","author":"Kao","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajg.2022.10.001_b0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.ajg.2022.10.001_b0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.14218\/JCTH.2018.00014","article-title":"Hepatitis C virus clearance by direct-acting antiviral results in rapid resolution of hepatocytic injury as indicated by both alanine aminotransferase and aspartate aminotransferase normalization","volume":"6","author":"Huynh","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajg.2022.10.001_b0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.14799","article-title":"Effectiveness, treatment completion and safety of sofosbuvir\/ ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study","volume":"48","author":"Butt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajg.2022.10.001_b0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11255-013-0459-2","article-title":"Nutritional predictors of early mortality in incident hemodialysis patients","volume":"46","author":"Lukowsky","year":"2014","journal-title":"Int Urol Nephrol"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168719792200079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168719792200079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:45:58Z","timestamp":1761659158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S168719792200079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S168719792200079X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2022.10.001","relation":{},"ISSN":["1687-1979"],"issn-type":[{"value":"1687-1979","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir-based therapy in HCV patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of Pan-Arab Association of Gastroenterology.","name":"copyright","label":"Copyright"}]}}